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Aims Infection is a serious complication of pacemaker (PM) systems. Although the rate of infection has been debated, the
figures are largely unknown. We therefore studied the incidence of PM infection and its associated risk factors in the
Danish population.
Methods
and results
Since 1982, all PM implantation and removal procedures performed in Denmark have been prospectively recorded in
the Danish Pacemaker Register. All patients (n ¼ 46299) who underwent implantation between 1982 and 2007 were
included. The total length of surveillance was 236 888 PM-years. The incidence of infection was calculated according
to the total number of PM-years. The incidence of surgical site infection (≤365 days after PM implantation) was com-
pared with later infection in first implant and replacement procedures. Multiple-record and multiple-event-per-subject
proportional hazards analyses were used to identify the independent risk factors of PM infection. Surgical site infection
occurred in 192 cases after first implantation (incidence rate 4.82/1000 PM-years), and in 133 cases after replacement
(12.12/1000 PM-years). Infections occurring more than 365 days after the first implantation occurred in 153 cases (1.02/
1000 PM-years), and in 118 cases after replacement (3.26/1000 PM-years). Independent factors associated with an
increased risk of PM infection were a greater number of PM operations (including replacements), male sex, younger
age, implantation during the earliest part of the study period, and absence of antibiotics (P, 0.001).
Conclusion The overall risk of infection after PM implantation was low. A greater number of operations augmented the risk of
infection. This should be taken into account when considering revisions of PM systems.
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Introduction
Implantation of a permanent pacemaker (PM) has been widely
accepted and implemented worldwide as the treatment of
choice for bradyarrhythmias.1
Infection in a permanently implanted PM is a serious compli-
cation. It may occur either as a surgical site infection (SSI), occur-
ring within 1 year after implantation,2 or as late-onset lead
endocarditis. Pacemaker implantation rates are on the rise world-
wide,1 and the population of patients living with a PM is growing.
* Corresponding author. Tel: +45 89495566, Fax: +45 89496102, Email: brock@dadlnet.dk
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2011. For permissions please email: journals.permissions@oup.com.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article
for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the
original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this
must be clearly indicated. For commercial re-use, please contact journals.permissions@oup.com.
European Heart Journal (2011) 32, 991–998
doi:10.1093/eurheartj/ehq497
 by guest on January 16, 2017
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
As a consequence, PM infections are also increasing. It has been
suggested that the relative rates of infection are increasing;3,4
however, no large studies support this suggestion, and the
overall statistics for PM infection remain largely unknown.
A number of small studies5–10 as well as one larger prospective
study11 have identified risk factors for infection in permanent PM
systems. However, the results of these studies are somewhat con-
tradictory, and the risk factors for such infections have not been
studied in a large cohort. The Danish Pacemaker Register (DPR),
a prospective record of all implantations and removals of perma-
nent PMs and PM-leads in Denmark since 1982, offers a unique
opportunity to study the short- and long-term incidences of infec-
tion in permanently implanted PM systems, as well as their associ-
ated risk factors.
Methods
Study group
All Danish patients who underwent PM implantation or reoperation
with changes in hardware between 1 January 1982 and 31 December
2007 were included in the study. Patients with an implanted
cardioverter-defibrillator (ICD) were excluded from the study. A
minor fraction had their first PM implanted before 1982; these patients
were included at the time of their first PM replacement. Patients were
followed from the first PM implantation after January 1982 until
death, loss to follow-up, discontinuation of PM treatment, or until
31 December 2007. Each patient’s vital status as of 31 December
2007 was obtained from the Central Population Registry.
The DPR contains data from all Danish patients who received a per-
manent PM after 1 January 1982. Data collection was based on reports
from all 14 centres in Denmark that perform implantations of perma-
nent PM systems. Five of these centres were high-volume university
clinics, and nine were non-university clinics with lower patient
volumes. The implantation practice in the study period has shifted
from unipolar leads with passive fixation to predominantly bipolar
leads with active fixation in the recent years. Cephalic cut-down was
used for venous access in more than half of the patients and epicardial
approach in ,1%.
Pacemaker treatment in Denmark is standardized through a national
reference program. All clinics adhered to these standards except for
one, in which no preoperative antibiotics were administered when
first-time PM implantations were performed. All clinics used preopera-
tive antibiotics for patients undergoing PM replacements or reopera-
tions. Local guidelines determined the type and dosage of antibiotics,
but these data are not available in the study. All reoperations that
involved changes to the implanted hardware were recorded in the reg-
ister, while reoperations without hardware changes were not. The
number of reoperations prior to actual implantation were counted
for each patient and included in the analysis.
The reason for replacement or removal of a PM was recorded as
‘normal-end-of-life’, ‘technical failure’, or ‘surgical reason’. The latter
category included the four sub-categories ‘infection’, ‘mechanical
protrusion’, ‘erosion’, or ‘wound pain’, which were considered to
be infected PM systems and constituted the primary outcome.
The infections were not sub-classified as either wound infection
or endocarditis, but all infections occurring within 1 year after PM
implantation were considered to be SSIs in accordance with
current guidelines.2 Infections occurring beyond this period were
categorized as late infections.
The indication for implantation of a permanent PM system was
recorded at the time of first implantation, according to a predefined
classification. This was divided into four major groups: atrioventricular
(AV) block, sinus node disease, atrial fibrillation with bradycardia, and
‘other’. The mode of pacing at first PM implantation was classified as
single chamber AAI- or VVI-pacing, or dual chamber DDD pacing
[including cardiac resynchronization therapy (CRT)]. A surrogate
index for the duration and complexity of the procedure was con-
structed by counting the number of pieces of hardware implanted
and removed during the same procedure.
Statistical analyses
Multiple-record and multiple-event per subject proportional hazards
analyses were used to identify independent risk factors of PM infection.
This model allowed the evaluation of time-dependent prognostic
factors and multiple events per subject. It also allowed for gaps in
the observations.
The factors considered in the univariate and multivariate analyses
are shown in Table 2. All factors except sex and indication for PM
implantation were considered to be time-dependent and were
allowed to change with each new implantation.
Separate preliminary models were analysed for first implantations
and replacements, as well as for early (≤365 days) and late (.365
days) infections. This analysis justified a model without interaction
terms.
Patients were censored at the time of death or other termination of
PM treatment, such as discontinuation of PM use upon upgrade to an
ICD system or loss to follow-up. Results are presented as hazard ratios
+95% confidence intervals for the univariate analysis. For the
multivariate analysis, only the risk factors in the final model are
presented. All tests were two sided, and the P-value threshold for sig-
nificance was 5%.
Incidence of PM infection was calculated as the rate of infection per
1000 device-days.12 Statistical analyses were performed using the R
software (version 2.7.1 for Windows).
Results
Patients
Patient characteristics at the time of first PM implantation are
shown in Table 1.
A total of 46 299 patients underwent one or more PM implan-
tations during the study period. The first implantation was per-
formed in 44 630 patients during the study period, and prior to
the start of the study period in 1669 patients. One or more PM
replacements were carried out in 8380 patients. A total of 2498
patients underwent one or more PM reoperations consisting of
lead replacements without PM replacement. The total follow-up
was 236 888 device-years.
During the study period, 26 552 deaths occurred. The number
of patients lost to follow-up was 170, and PMs were removed
without replacement in 342 patients. The remaining 19 235
patients were living with an implanted PM at the end of the
study period. The total number of PMs implanted during the
study period was 56 657.
A subgroup of 902 patients in the DDD group received a CRT
system as a first time implant. In total, 1127 CRT devices were
implanted.
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Infections
A total of 596 PMs were removed due to infection: 345 after the
first PM implantation (incidence 1.82/1000 PM-years) and 251 after
replacement (incidence 5.32/1000 PM-years).
‘Infection’ was listed as the reason for removal of these PMs in
461 cases (77.3%); a minority of removals were attributed to other
clinical presentations of infection, such as ‘mechanical protrusion’
in 77 cases (12.9%), ‘erosion’ in 44 cases (7.4%), and ‘wound
pain’ in 14 cases (2.3%).
In 542 of these patients, one PM removal was performed due to
infection, and 27 patients underwent two PM removals.
The time to PM infection is illustrated by Kaplan–Meier plots in
Figure 1.
Surgical site infection (≤365 days after PM implantation)2
occurred in 192 cases after the first PM implantation (incidence
rate 4.82/1000 PM-years), and in 133 cases after PM replacement
(12.12/1000 PM-years). Infections after 365 days post-implantation
occurred in 153 cases after first PM implantation (1.02/1000
PM-years), and in 118 cases after PM replacement (3.26/1000
PM-years).
The risk of SSI was significantly higher than the risk of infection
after 365 days post-implantation for both first implantations and
replacement procedures. The risk of SSI relative to the risk of
later infection did not differ significantly between first implan-
tations and replacement procedures.
Risk factors associated with infection
Univariate proportional hazards analyses indicated that all poten-
tial risk factors studied were significant, except for high-volume
centre vs. low-volume centre and for prior infection (Table 2).
In summary, the following factors were associated with an
increased risk of PM removal due to infection: PM replacement
vs. first PM implantation, male sex, younger age, implantation
during the earliest part of the study period, absence of prophy-
lactic antibiotics (but only for first PM implantations), dual
chamber pacing mode, AV block as an indication for pacing,
greater number of PM operations, and greater complexity of
the procedure.
In the multivariate analyses, ‘prior procedures’ was included as a
variable. A large number of these prior procedures consisted of
PM replacements, and therefore the variable ‘first PM implantation
vs. PM replacement’ was excluded from the multivariate analyses.
In the final multivariate statistical model, pacing mode, indication
for pacing, and complexity of the procedure were not found to
be significantly associated with a risk of PM infection. Thus, the fol-
lowing risk factors were independently associated with an
increased risk of PM removal due to infection in the final multi-
variate model: male sex, younger age, implantation during the ear-
liest part of the study period, absence of prophylactic antibiotics
(during the first PM implantation), and greater number of PM oper-
ations (Table 2).
Discussion
To our knowledge, the present study represents the largest
population-based study of PM infections and associated risk
factors to date and reports reliable rates for the risk of infection
after first PM implantations and PM replacements. Repeated
operative procedures after the first PM implantation were
associated with a substantial incremental risk of PM infection.
Conversely, female sex, older age, and preoperative antibiotics
given at the first PM implantations were associated with a
lower risk of later PM infection. The pacing mode, indication
for pacing, and complexity of the procedure were not indepen-
dently associated with the risk of later PM infection. Although
the majority of infections occurred within the first year of
follow-up, a large number of infections were found to occur
during the late follow-up period, .1 year post-implantation.
This very late onset of infection is consistent with the findings
from other studies that consider extended follow-up periods8–10
and with the current understanding of slowly progressing,
implant-related infection.13 The defined 1 year period post-implant
surgery for SSI may be more or less arbitrary,2 and in our study
we were not able to distinguish between clinical SSI and lead
endocarditis. The significant number of infections occurring later
than 1 year after implantation highlights the continued need for
long-term clinical follow-up of PM patients.
Rates of infection
The incidence of PM in our population was 1.82 per 1000
PM-years after the first implantation. This is similar to the rate of
1.9 per 1000 device-years reported in a smaller, retrospective,
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Table 1 Patient characteristics
Variable Patients at first pacemaker
implant (n5 44630)
Sex (n, %)
Male 24 023, 53.8%
Female 20 607, 46.2%
Age (median, 25–75%
interquartile range)
76, 68–82
Pacing mode (n, %)
AAI 4084, 9.2%
VVI 20 140, 45.1%
DDD 19 504, 43.7%
CRT 902, 2.0%
Indication (n, %)
AV block 19 408, 43.5%
Sick sinus syndrome 14 598, 32.7%
Atrial fibrillation 6258, 14.0%
Other 4366, 9.8%
Complexity of the procedurea
2 24 210, 54.2%
3 19 603, 43.9%
4+ 817, 0.8%
aA surrogate index for the duration and complexity of the procedure was
constructed by counting the number of hardware pieces implanted and removed
during the same procedure.
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population-based cohort study.9 Other epidemiological studies
that include long-term follow-up have calculated cumulative rates
per patient or device and report infection rates of 2.210 and
1.6%,8 respectively. Studies examining shorter follow-up periods
report infection rates of only 0.6811 and 1%.14 However, these
studies failed to report weighted incidences.12 In contrast to our
study, these prior studies also reported infections after implan-
tation of ICD systems. The effect of this difference is unclear;
the rate of infection in ICD systems has been reported to be
similar to the rates observed for PM systems,8,10,11 with the excep-
tion of one study that demonstrated a higher risk of infection in
ICD patients.11 This is likely explained by the higher proportion
of abdominal, non-transvenous ICD systems.
The incidence of SSI was 4.82/1000 PM-years after first PM
implantation and 12.12/1000 PM-years after PM replacement.
This is comparable with the rates observed in other fields of pros-
thesis implant surgery, as a recent extensive review of 1707 cases
of hip and knee arthroplasty demonstrated SSI rates of 1.32 and
1.83%, respectively.15 Although the setting described in the
review differs from that of our study and there is a general lack
of data on SSI in implant surgery, we find our incidences of SSI
in PM implantation to be acceptable.
Based on estimates from Medicare3 and the National Hospital
Discharge Survey,4 the incidence of infections in implanted
devices is assumed to be rising. This assumption could not be
confirmed in the present population-based study, which demon-
strated a fairly constant rate of infection after implantation of
permanent PM systems over the past 20 years. The rate of
infection after implantation of more complex CRT systems in
patients with severe heart failure within the last decade may
be higher, but it has not yet been studied in suitably large
patient cohorts.
Prior procedures
The substantially elevated risk of infection after PM replacements
and other repeated procedures observed in the present study
has been reported previously.8,10,11,16 A recent randomized trial
found a higher rate of infection after first implantations compared
with after PM replacements.17 In this trial, however, follow-up was
carried out for only 6 months, and the number of infected patients
reached 13 in the two treatment arms. Four of these patients pre-
sented with superficial infections that were treated with antibiotics.
The increased risk of infection after repeated procedures argues
strongly that industry should improve PM batteries and that phys-
icians should increase device longevity by appropriately program-
ming PM parameters. Furthermore, the increased risk of
infection after repeated procedures should be considered in the
decision-making process when handling device recalls,18 which
are a common reason for premature repeated procedures. In
each patient, the benefits of replacing the hardware should be
balanced with the increased risk of device infection.
At first glance, the higher risk of infection after repeated pro-
cedures (most often simple PM replacements) is unexpected, as
these procedures most often involve only a minor surgical revision
and are short-lasting compared with first implantations. It is gener-
ally recognized, however, that revision surgery is an important risk
factor for the infection of an implanted prosthesis or device.19 Our
findings could likely be explained by the fact that PM pockets can
be colonized by bacteria, even in the absence of any initial clinical
signs of infection.20 In combination with the limited immunological
response of the fibrous and poorly vascularized PM pocket that is
opened during replacement or revision procedures,21 the rapid
formation of a microbial biofilm22 by either latent or perioperative
inoculation of pathogens may be favoured, thereby allowing pocket
infection.
Figure 1 Kaplan–Meier plot of the time to infection after first pacemaker implantation (n ¼ 44631) and after pacemaker replacements
(n ¼ 8380).
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Table 2 Infection of pacemaker systems and its associated risk factors
Variable Devices Device-years Events Univariate Multivariatea
Hazard ratio95% CI P-value Hazard ratio95%
CI
P-value
Implantation
First 44 630 189 687 345 1 ,0.001 b
Replacement 12 027 47 201 251 2.79(2.38–3.28)
Infection
≤365 days 56 657 50 821 325 1 ,0.001 1 ,0.001
.365 days 45 420 186 067 271 0.16(0.08–0.31) ,0.001 0.35(0.17–0.61)
Sex
Male 30 294 121 238 384 1 ,0.001 1 ,0.001
Female 26 363 115 650 212 0.60(0.51–0.71) 0.67(0.57–0.80)
Age
0–19 571 2499 22 1.63(0.96–2.78) 1.41(0.83–2.38)
20–49 2551 14 352 69 1 ,0.001 1 ,0.001
50–59 3938 21 045 9 0.75(0.55–1.03) 0.79(0.58–1.08)
60–69 9527 46 552 150 0.62(0.47–0.83) 0.68(0.51–0.90)
70–79 19 186 86 155 181 0.39(0.29–0.51) 0.44(0.34–0.59)
80–89 17 812 59 396 89 0.24(0.17–0.32) 0.29(0.21–0.39)
90– 3072 6888 6 0.11(0.05–0.25) 0.31(0.06–0.30)
Year of implantation
1982–84 2033 14 357 63 1 ,0.001 1 ,0.001
1985–89 7614 46 755 102 0.53(0.39–0.72) 0.58(0.43–0.78)
1990–94 8618 44 937 89 0.44(0.32–0.59) 0.45(0.33–0.61)
1995–99 10 693 53 120 105 0.41(0.31–0.56) 0.42(0.31–0.56)
2000–04 16 146 62 560 144 0.42(0.32–0.55) 0.40(0.31–0.53)
2005–07 11 553 15 159 93 0.65(0.47–0.89) 0.60(0.44–0.82)
High volume centre
No 37 764 167 489 425 1 0.160
Yes 18 893 69 398 171 0.88(0.73–1.06)
Preoperative antibiotics
Yes 51 473 213 911 516 1 ,0.001 1 ,0.001
No 5184 22 976 80 2.27(1.76–2.91) 2.33(1.81–2.98)
Pacing mode
AAI 4874 22 116 42 1 0.005
VVI 25 334 115 482 245 1.18(0.84–1.65)
DDD 26 449 99 289 309 1.49(1.07–2.08)
Indication
AV block 24 854 103 365 322 1 ,0.001
Sick sinus syndrome 18 452 80 358 151 0.61(0.50–0.75)
Atrial fibrillation 7354 25 521 44 0.51(0.37–0.69)
Other 5997 27 644 79 0.89(0.76–1.26)
Prior procedures
0 44 556 186 357 323 1 ,0.001 1 ,0.001
1 9235 38 701 180 2.62(2.19–3.14) 2.74 (2.27–3.31)
2 2035 8784 57 3.69(2.78–4.88) 3.76 (2.78–5.08)
3 586 2268 20 5.80(4.04–8.33) 5.49 (3.71–8.13)
4+ 245 775 16 11.02(4.89–24.8) 8.68 (3.63–20.8)
Continued
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Preoperative antibiotics
No single, sufficiently powered randomized trial has been per-
formed to evaluate the effects of preoperative antibiotics on the
long-term incidence of infection in PM treatment. A meta-analysis
performed in 1998 revealed that preoperative administration of
prophylactic antibiotics is effective in reducing the risk of infec-
tion,23 and antibiotic prophylaxis before PM implantation has
been recommended for the last decade.2,24 The omission of sys-
temically administered prophylactic antibiotics during the first
implantation was confirmed to be an important risk factor for
infection in the present study, whereas prophylactic antibiotics
were used in all reoperations. Other studies11,17,25 confirming
the beneficial effects of antibiotics, irrespective of the dosing
regimen used, have included both first PM implantations and reo-
perations. To date, however, no study has separately analysed the
effects on first implantations vs. reoperations. The immune
response is altered in the device pocket as a consequence of the
presence of a foreign body,21,26 and antimicrobial agents have
been shown to have a limited effect on biofilm-associated bacterial
infections.27 It has therefore been suggested that the future antimi-
crobial strategy employed in implantation surgery should include
local antimicrobial applications,28 although such an approach has
not been tested in prospective trials.
Other procedure-related factors
A higher rate of infection was observed during the earliest period,
from 1982 to 1984, than during the subsequent 23 years. A poss-
ible explanation for these findings is that these procedures were
often shared by thoracic surgeons and cardiologists, thus making
the procedure more complicated.
In contrast, three potentially important procedure-related
factors—the size of the implanting centre, the complexity of the
procedure, and the number of leads—did not influence the rate
of infection. This is consistent with the results of previous
studies.10,11 These results underscore the importance of other
procedure-related factors, namely the use of preoperative anti-
biotics and repeated procedures.
In Denmark, implantation of PMs is performed only in hospitals
with a fairly high implantation volume, and the majority of pro-
cedures are carried out by experienced cardiologists.29 Thus, the
present findings regarding higher- and lower-volume centres
cannot necessarily be generalized to clinics with limited experience
and/or a very low implantation volume (, 50 PM implantations
per year).
Patient factors
We found that male sex was an important risk factor, consistent
with the findings of Catanchin.8 Surprisingly, we observed an
inverse relationship between increasing age and the risk of infec-
tion, with the rate of infection highest in children and adolescents
and declining with age. Prior studies8–11 have not demonstrated
this relationship between age and infection rate, most likely due
to the presence of low numbers of children and adolescents in
their study populations. Young patients are more likely to
possess non-transvenous systems, which bear a higher rate of
infection.30 For reasons that remain unclear, the declining risk of
infection with age was sustained in older age groups. Factors
such as the presence of less firm subcutaneous connective
tissue, which would permit less traumatic formation of the PM
pocket, as well as a less aggressive immune response against low-
virulence bacteria with increasing age could theoretically play a
role. Another possibility is that physicians might be more reluctant
to perform a full and potentially hazardous extraction procedure in
elderly, more fragile PM patients, and may therefore pursue a more
conservative treatment.
Limitations
The present study is a retrospective analysis, and thus bears the
inherent limitations of such studies. The data, however, were
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 2 Continued
Variable Devices Device-years Events Univariate Multivariatea
Hazard ratio95% CI P-value Hazard ratio95%
CI
P-value
Complexity of the procedurec
2 28 887 131 238 262 1 ,0.001
3 24 144 91 674 254 1.22(1.02–1.46)
4 3626 13 974 80 2.56(1.98–3.32)
Prior infection
No 11 345 46 588 239 1 0.120
Yes 682 612 12 1.58(0.89–2.80)
Results of univariate and multivariate proportional hazards analyses.
aFor the multivariate analysis, only the risk factors in the final model are presented.
bThe variable ‘first pacemaker implantation vs. pacemaker replacement’ was excluded from the multivariate analyses, as a large number of the ‘prior procedures’ consisted of PM
replacements.
cA surrogate index for the duration and complexity of the procedure was constructed by counting the number of hardware pieces implanted and removed during the same
procedure.
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reported prospectively to the register, reducing some of these
limitations. With a 25-year-long period of reporting and
follow-up, we find it very unlikely that the data are flawed by
systematic bias caused by single operators or clinics. The DPR,
however, has been subject to an external audit documenting
the quality of the data.29
Any reporting of complications to a register is subject to under-
reporting, as well as to inappropriate classification of the causal
explanation at the time of PM removal. The infection rates
observed therefore represent minimal numbers, with a risk of
underestimating the problem. Furthermore, the DPR was not
exclusively set up to monitor device infections, and several poten-
tial risk factors such as renal dysfunction and diabetes mellitus
were not available in the current analysis. The large number of
patients and the completeness of follow-up should counterbalance
the inherent weakness of registry-based studies.
We were not able to distinguish whether removal of the PM
system was due to infection arising from a device pocket infection
or from a bloodstream infection of the intravascular portion of the
system. However, data suggest an overlap between these two
events.5,31
Conclusion
The incidence of infection after first PM implantation was 1.82/1000
PM-years in this nationwide cohort of 46 299 consecutive PM
patients with long-term follow-up. The rate of infection was signifi-
cantly higher after PM replacement procedures, for which 5.32/1000
PM-years was observed. Repeated operative procedures after the
first PM implantation were associated with a substantial incremental
risk of PM infection. Female sex, older age, and administration of
preoperative antibiotics in the first PM implantation were associated
with a decreased risk of later PM infection. Pacing mode, indication
for pacing, and procedure complexity were not independently
associated with the risk of later PM infection.
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Imaging of perimyocardial sarcoidosis during successful treatment
Stefan Buchner1*, Andreas Luchner1, Okka W. Hamer2, and Kurt Debl1
1Klinik und Poliklinik fu¨r Innere Medizin II, Universita¨tsklinikum Regensburg, Franz-Josef-Strauss-Allee 11, Regensburg 93042, Germany and 2Institut fu¨r Ro¨ntgendiagnostik,
Universita¨tsklinikum Regensburg, Franz-Josef-Strauss-Allee 11, Regensburg 93042, Germany
* Corresponding author. Tel: +49 941 944 7211, Fax: +49 941 944 7213, Email: stefan.buchner@klinik.uni-regensburg.de
A 29-year-old previously healthy man pre-
sented with progressive dyspnoea and a
history of recurrent arthritic symptoms.
Transthoracic echocardiography revealed
a dilated left ventricle with a global hypokine-
sia and thickened pericardium (Panel A; see
Supplementary material online, Movie SI).
Cardiovascular magnetic resonance
(CMR) showed global hypokinesia of the
left and right ventricles with a predominant
akinesia of the left ventricular lateral wall
and marked pericardial thickening (Panel B;
see Supplementary material online, Movie
SII). Delayed enhancement images disclosed
extensive hyperenhancement of the entire
peri/epicardium and mainly in the subepicar-
dial anterolateral myocardium (Panel C,
arrows). In addition, enlarged hilar and med-
iastinal lymph nodes were noted. By endobronchial lymph node biopsy, the diagnosis of sarcoidosis was made. After the medication
with steroids (prednisolone 1 mg/kg body), the patient improved rapidly (Panel D; see Supplementary material online, Movie SIII). After
6 weeks, CMR follow-up showed an improvement of left ventricular function (Panel E; Movie IV) and a marked reduction of delayed
enhancement (Panel F).
Supplementary material is available at European Heart Journal online.
Panel A. Transthoracic echocardiogram, apical four-chamber view, shows an impaired left ventricular function and a thickened
pericardium (see Supplementary material online, Movie SI).
Panel B. Cardiovascular magnetic resonance (four-chamber view) demonstrates the distinct thickness of the epi- and pericardium,
resulting in an impaired systolic and diastolic left ventricular function (see Supplementary material online, Movie SII).
Panel C. Delayed-enhanced magnetic resonance imaging reveals severe circular hyperenhancement of the entire epi/pericardium and
of the subepicardial anterolateral myocardium (white arrows).
Panel D. Two weeks after steroid therapy, transthoracic echocardiography (apical four-chamber view) shows an improved left ven-
tricular function (see Supplementary material online, Movie SIII).
Panel E. Six weeks after steroid therapy, cardiovascular magnetic resonance (four-chamber view) demonstrates a marked regression
of the epi/pericardial inflammation and an improved systolic and diastolic left ventricular function (see Supplementary material online,
Movie SIV).
Panel F. Six weeks after steroid therapy, areas of hyperenhancement in the epi/pericardium and the anterolateral supepicardial myo-
cardium are considerably decreased.
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